Expanding Diagnostic Services Provista Diagnostics has recently launched PCR testing for urinary tract infections, wounds, and respiratory pathogens, indicating an active growth phase in diagnostic testing capabilities which presents opportunities for partnerships or supply chain solutions.

Focus on Women's Health The company's development of the Videssa Breast Cancer Blood Test underscores a targeted focus on women’s health diagnostics, opening avenues for collaborations with hospitals, clinics, and health systems focusing on early cancer detection services.

Strategic Acquisitions Having been acquired by Todos Medical for $10 million, Provista’s unique proprietary tests and CLIA/CAP certifications position it as an attractive partner for expansion into additional diagnostic markets and institutional client bases.

Investments in Innovation With a dedicated investment of 100% of COVID-19 PCR testing profits into developing new diagnostic solutions, Provista is poised to introduce innovative tests that can meet emerging clinical needs, offering opportunities for early adoption and sales of cutting-edge diagnostics.

Growing Market Presence Operating with a modest employee base and revenue between 1 million to 10 million dollars, Provista’s expansion in Florida and its focus on early detection tests present potential for scalable sales efforts across broader markets and health sectors.